| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $5,801 | $8,185 | $4,410 | -$68 | $426 | $20 |
| Operating Margins | -370% | -669% | -2197% | 129029% | -22519% | -515860% |
| Net Margins | -354% | -599% | -2201% | 124578% | -20762% | -475295% |
| Net Income (k) | -$20,520 | -$49,044 | -$97,090 | -$84,713 | -$88,447 | -$95,059 |
| Net Interest Expense (k) | $2 | $9 | $5 | $8 | $35 | $8,113 |
| Depreciation & Amort. (k) | $240 | $429 | $551 | $493 | $477 | $238 |
| Diluted Shares (k) | 13,125 | 25,637 | 41,283 | 46,926 | 53,247 | 71,003 |
| Earnings Per Share | -$1.6 | -$1.91 | -$2.35 | -$1.81 | -$1.66 | -$1.34 |
| EPS Growth | n/a | -19.37% | -23.04% | 22.98% | 8.29% | 19.28% |
| Avg. Price | $2.42 | $9.97 | $13.12 | $6.97 | $11.25 | $4.02 |
| P/E Ratio | -1.51 | -5.22 | -5.58 | -3.85 | -6.78 | -3.0 |
| Free Cash Flow (k) | -$9,603 | -$34,510 | -$90,355 | -$62,712 | -$75,857 | -$79,610 |
| CAPEX (k) | $1 | $204 | $12,117 | $126 | $47 | $238 |
| Current Ratio | 10.04 | 19.16 | 11.17 | 11.31 | 17.26 | 13.11 |
Altimmune Inc. is a company with potential, but currently faces challenges that make it appear overvalued. The company's negative earnings growth rate and declining revenues of -69.0% annually raise concerns about its financial health. However, Altimmune is making significant reinvestments into the business, with capital expenditures growing at a rate of 18.3%. Additionally, its earnings per share have shown a modest annualized growth rate of 2.9% over the past 6 years.
Altimmune's negative trailing twelve month earnings per share make its P/E ratio not meaningful, and its consistently negative free cash flows of $-58.77 million over the last 5 years, with a growth rate of -52.7%, indicate the company's financial struggles.
On a positive note, Altimmune boasts a strong current ratio of 13.11, indicating that its current assets of $137.25 million far exceed its current liabilities of $10.47 million. Additionally, its Price to Book Ratio of 2.01 is lower than the sector average of 3.19, suggesting that the stock might be undervalued in comparison to its assets.
